Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

Breast Cancer Research and Treatment

Volumn 148, Issue 2, 2014, Pages 397-406

  Chai, Xinglei ^a   Friebel, Tara M ^a,b   Singer, Christian F ^c   Evans, D Gareth ^d   Lynch, Henry T ^e   Isaacs, Claudine ^f   Garber, Judy E ^g   Neuhausen, Susan L ^h   Matloff, Ellen ⁱ   Eeles, Rosalind ^j   Tung, Nadine ^k   Weitzel, Jeffrey N ^h   Couch, Fergus J ^l   Hulick, Peter J ^m,n   Ganz, Patricia A ^o   Daly, Mary B ^p   Olopade, Olufunmilayo I ^q   Tomlinson, Gail ^r   Blum, Joanne L ^s   Domchek, Susan M ^a,b   Chen, Jinbo ^a   Rebbeck, Timothy R ^a,b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e CREIGHTON UNIVERSITY   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ YALE UNIVERSITY   (United States)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^l MAYO CLINIC   (United States)

^m NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p FOX CHASE CANCER CENTER   (United States)

^q UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^r UNIVERSITY OF TEXAS   (United States)

^s BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

BRCA1; BRCA2; Risk reduction; Surgical prevention; Uptake

Indexed keywords

ADULT; AGE; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; CORRELATIONAL STUDY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PREGNANCY; PROSPECTIVE STUDY; RISK REDUCTION; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE; AGED; BREAST NEOPLASMS; CANCER STAGING; FOLLOW UP; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; SURVIVAL RATE; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SURVIVAL RATE; YOUNG ADULT;

EID: 84911979243     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3134-0     Document Type: Article

References (29)

1. J. Balmaña, O. Díez, I.T. Rubio, F. Cardoso, E.G.W. Group, BRCA in breast cancer: ESMO Clinical Practice Guidelines, Ann Oncol 22 Suppl 6 (2011) vi31-34
2. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J (2009) Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomark 13:51–56
3. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333
4. Collins IM, Milne RL, Weideman PC, McLachlan SA, Friedlander ML, Hopper JL, Phillips KA, K.C.F.C.F.R.I.F.B. Cancer (2013) Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. Med J Aust 199:680–683
5. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van’t Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229
6. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t’veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975
7. Domchek SM, Stopfer JE, Rebbeck TR (2006) Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Compr Cancer Netw 4:177–182
8. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547–1553
9. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR (2007) Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7:875–882
10. Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB (2013) Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol 132(2):428–433
11. A.C.o.O.a. Gynecologists, A.C.o.P. Bulletins–Gynecology, A.C.o. Genetics, S.o.G. Oncologists (2009) ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957–966
12. Kauff N, Domchek S, Friebel T, Robson M, Lee J, Garber J, Isaacs C, Evans G, Lynch H, Eeles R, Neuhausen S, Daly M, Matloff E, Blum J, Sabbatini P, Hudis C, Norton L, Barakat R, Offit K, Rebbeck T (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multi-center, prospective study. J Clin Oncol 26:1331–1337
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615
14. Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS (2013) Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. JAMA Intern Med 173(2013):96–103
15. Menon U, Griffin M, Gentry-Maharaj A (2014) Ovarian cancer screening—current status, future directions. Gynecol Oncol 132:490–495
16. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017–2022
17. Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 4:97–103
18. NCCN, NCCN guidelines for detection, prevention, and risk reduction: genetic/familial high risk assessment: breast and ovarian (v 2.2013). Cancer guidelines , 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection
19. Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck S (2011) Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 13:148–154
20. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, Evans E, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622
21. Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Büttner R, Ulrich U, Schmutzler RK (2011) Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283:623–627
22. Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L (2012) Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 118:510–517
23. Morgan D, Sylvester H, Lucas FL et al (2009) Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 8:277–87
24. Morgan D, Sylvester H, Lucas FL et al (2010) Perceptions of high-risk care and barriers to care among women at risk for hereditary breast and ovarian cancer following genetic counseling in the community setting. J Genet Couns 19:44–54
25. Foster C, Watson M, Eeles R et al (2007) Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three year follow-up. Br J Cancer 96:718–24
26. Madalinska JB, van Beurden M, Bleiker EM et al (2007) Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 25:301–7
27. Mahon SM (2001) Factors affecting genetic testing and decisions about prophylactic surgery. Clin J Oncol Nur 5:117–20
28. Watson M, Foster C, Eeles R et al (2004) Psychosocial impact of breast/ovarian (BRCA1/2) cancer predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer 91:1787–94
29. Miller SM, Roussi P, Daly MB et al (2010) New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16:5094–106